Boston Children's Hospital

Apertura Gene Therapy has licensed its novel TfR1 CapX capsid technology to Galibra Neuroscience and Emugen Therapeutics for central nervous system gene therapy programs.

A comprehensive analysis of insulin out-of-pocket costs and usage patterns from 2008-2021 reveals persistent disparities in insulin access between higher-income and lower-income patients with diabetes.

Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs have formed BrightSeq, a collaborative initiative to develop clinical molecular testing assays specifically for pediatric cancers.

The first commercial gene therapy treatments ever delivered directly to the brain in the United States have been successfully performed using ClearPoint Neuro's SmartFlow Neuro Cannula to administer KEBILIDI for AADC deficiency.

NS Pharma's parent company Nippon Shinyaku has finalized a strategic partnership with Boston Children's Hospital to develop innovative therapies for rare diseases.

Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).

Children with uncontrolled moderate to severe asthma experienced significantly fewer exacerbations when treated with dupilumab compared to placebo, regardless of how long they had been living with the disease.

The FDA has cleared BlackfinBio's IND application to begin a Phase 1/2 clinical trial of BFB-101, a gene therapy designed to treat Hereditary Spastic Paraplegia Type 47 (SPG47), a rare neurological disorder with no existing treatments.

Luminopia's VR-based digital therapeutic for amblyopia has received FDA clearance for children aged 8-12 years, expanding from its previous 4-7 year age indication based on robust real-world evidence.

Recent research published in JAMA predicts millions of preventable disease cases over the next 25 years if childhood vaccination rates continue to decline from their current level of under 93%.